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S U M M A R Y
Cellular therapy now offer promise of potential adjunct therapeutic options for treatment of drug-
resistant tuberculosis (TB). We review here the role of Mesenchymal stromal cells, (MSCs), as well as
other immune effector cells in the therapy of infectious diseases with a focus on TB. MSCs represent a
population of tissue-resident non-hematopoietic adult progenitor cells which home into injured tissues
increase the proliferative potential of broncho-alveolar stem cells and restore lung epithelium. MSCs
have been shown to be immune-modulatory and anti-inﬂammatory mediated via cell-cell contacts as
well as soluble factors. We discuss the functional proﬁle of MSCs and their potential use for adjunct
cellular therapy of multi-drug resistant TB, with the aim of limiting tissue damage, and to convert
unproductive inﬂammatory responses into effective anti-pathogen directed immune responses. Adjunct
cellular therapy could potentially offer salvage therapy options for patients with drug-resistant TB,
increase clinically relevant anti-M.tuberculosis directed immune responses and possibly shorten the
duration of anti-TB therapy.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Mesenchymal stromal cells (MSCs) represent a population of
tissue-resident non-hematopoietic adult progenitor cells, origi-
nally identiﬁed in the bone marrow,1 and subsequently in a
number of other organs.2,3 MSCs were identiﬁed in the 1970s from
cellular suspensions from spleen and bone marrow by their
capacity to adhere to plastic – which is still the standard form for
culturing MSCs. MSCs are able to form colonies from single cells
(explanted ex vivo), have ﬁbroblast-like appearance and capacity to
differentiate into fat, cartilage and bone. Their function in bone* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).marrow is to facilitate haematopoiesis for expansion of hemato-
poietic and embryonic stem cells,4,5 thus may play a role in
stimulating cell growth and organization in adult organ tissues.2
MSCs have been shown to increase the proliferative potential of the
so-called bronchoalveolar stem cells6 and to restore lung
epithelium via the transfer of mitochondria to other cells.7,8 MSCs
are deﬁned by CD105, CD90 and CD73 expression and negative for
CD45, CD34 and CD14.9,10 More recent studies show that isolation
of MSC from patients with underlying diseases may lead to
different phenotypes, mantaining CD105, CD90 and CD73 expres-
sion. Bone-marrow derived MSCs may thus represent a mixture of
different MSC populations11 as has also been shown to be true for
MSC from lung tissue. Sabatini showed in 20053 that a plastic
adherent cell population exists in human lungs isolated via BAL12
or via tissue digestion.13 These cells are either long-lived or – not
mutually exclusive – have the capacity for renewal. Given the fact
that MSCs support human stem cells in the bone marrow, as well as
bronchoalveolar stem cells, it is most likely that these functionsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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damaged lung tissue may aid to re-organize tissue and facilitate
healing of chronic, unproductive inﬂammation associated with
Mcyobacterium tuberculosis (Mtb) infection.
MSCs are believed to be facilitators of organ homeostasis and
tissue repair following infection, neoplasms, damage and ‘trauma’ in
general. MSCs are key cells in connective tissue hierarchy of organs,
including the lungs. The roles of MSCs in the lung have recently been
extensively reviewed by Sinclair and coworkers.14 MSCs have been
shown to be immune-modulatory, anti-inﬂammatory and immune-
suppressive and most studies have looked at these effects in the
allogeneic setting. In vitro, MSCs may decrease immune effector
functions and aid to expand regulatory T-cells. Both cell-cell
contacts as well as soluble factors could be mediating these
effects15,16 particularly on precursor and memory T-cell subpopula-
tions.16–18 Cell-cell contact appears to be important for expansion of
Treg cells, deﬁned by the CD4+CD25high, Foxp+ phenotype.19,20 The
functions of MSCs may be diverse and dictated by the immune-
environment; thus making it difﬁcult to predict how MSC will work
in patients with lung tissue ﬁlled with live Mtb bacilli. For instance,
co-culture of MSCs with PBMCs leads to prostaglandin E2 (PGE2)
production in MSCs,21 PGE2 and COX2 are increased in the presence
of type I interferons and/or TNFa suggesting that the effect of MSCs is
inﬂuenced by the local cytokine milieu.15,22
The production of PGE2
4,23 from MSCs may be particularly
important in balancing unproductive inﬂammation in TB: High
type I interferon levels affect TB disease outcome, increases tissue
damage and subsequently increased Mtb proliferation. PGE2
balances the inﬂammatory cytokines IL-1 and type-I interferons
in individuals with latent TB; modulation of this host immune
response axis has proven to be effective in preventing death in
Mtb-infected mice. Studies in mice and analysis of ex vivo material
from patients with TB demonstrated that IL-1 induces PGE2 and
suppresses type I interferons linked with clinical TB outcome.24
Environmental factors (metabolic programming), e.g. oxygen
levels, have also been shown to inﬂuence the differentiation of MSCs
into articular cartilage or epiphyseal cartilage.25Of note, more recent
studies suggest that MSC may not only differentiate into fat, cartilage
or bone, but also into bronchial epithelium, renal epithelium,
neuronal tissue as well as cardiomyocytes. This is reﬂected in a
number of studies using MSCs for non-mesenchymal tissues
including brain, heart, and kidney diseases.26 Several studies have
now shown that clinical efﬁcacy is not directly related to successful
expansion and the level of MSC engraftment, yet to other factors
(paracrine), driven by MSCs, which are yet to be identiﬁed. One of the
aspects of MSCs is the polarization into pro- or anti-inﬂammatory
cells, which appears to be triggered, at least in part, via TLRs. MSCs
express TLR3 and TLR4. TLR3-agonists appear to polarize MSC to
immune-suppression, whereas TLR4 stimulation leads to immune-
stimulation of MSCs.27 Several components of Mtb signal via TLRs
and the local effect of MSC - in combination with the cytokine milieu
and the TLRs – will contribute to the Mtb edited phenotype. One of
the factors in Mtb infection is lung destruction via ﬁbrosis and
collagen synthesis, which is – in part – a TGFb driven process. We
showed that non-human primates that survive longer after Mtb
challenge have a typical immune phenotype in their lungs, deﬁned
by less ﬁbrosis, decreased TGFb production and increased IL-7 and
IL-17 production.28 Of interest, TGFb production has been shown to
be repressed in TLR3-edited, yet not in TLR4-stimulated MSCs;27
TLR3-primed MSCs showed up to the 80% reduced TGFb production,
which is mediated via TLR3-induced modulation of TGFb –
downstream effectors SMAD3 and SMAD7; TLR3 versus TLR4
stimulated MSCs also show differential IDO and PGE2 production,
which also underlines the local immune-editing milieu of Mtb
infected tissues. PGE2 converts macrophages into an IL-10 –
producing phenotype. Immunomodulatory properties include theproduction of IL-1 receptor antagonists and the TSG-6 protein (anti-
inﬂammatory protein TNFa stimulated gene protein 6).29
A number of clinical trials using MSCs as immune-modulatory
agents or as stimulators for tissue generation have been reported.
MSCs are being used for corticosteroid-resistant Graft versus Host
Disease (GVHD) (i.e. inﬂammatory reactions after hematopoietic
stem cell transplantation), and for treatment of other autoimmune
diseases (Multiple Sclerosis, Crohn’s disease etc.).30,31 Sinclair and
colleagues14 in their phase I clinical study of MSC infusions in an
allogeneic setting established safety of the allogeneic MSC infusion,
with 2 x 106 cells / kg i.v. twice weekly for two weeks. The aim was to
offer MSC for treatment of complications after lung transplantation
as well as for the treatment of idiopathic lung ﬁbrosis (www.
clinicaltrial.gov). Another study evaluated the intra-tracheal ad-
ministration of umbilical cord derived MSCs in children with
bronchopulmonary dysplasia (www.clinicaltrials.gov/ct2/show/
NCT01297205).
2. MSCs and infection
MSCs are susceptible to infection by several intracelullar
pathogens such as Mtb, Inﬂuenza virus30 and Herpesvirus-6
infection.32 Conversely, MSCs have been shown to improve
survival33 in bacterial infections of mice which supports the concept
as stated above that organ-damaging cascades in infections can be
curbed with MSC treatment:34 MSCs reduce inﬂammation–associ-
ated lung damage.35,36 The safety of MSC therapy has recently been
extensively reviewed by Lalu and coworkers.37 Other beneﬁcial
effects may be the production of exosomes and microvesicles from
MSCs which has been studied in the interaction of MSC and cancer
cells,38 but not in the context of MSC and pathogens. This is also a
potential new area of investigation: if the signalling proteins and
miRNA in the exosomes and microvesicles can be identiﬁed,
potentially the cell therapy infusions can be obviated to the far
simpler protein/miRNA infusions – if exosomal delivery of signals
and proteins turns out to be biologically and clinically relevant in
infections. Nauta and Fibbe reviewed the immunomodulatory
properties of MSCs and showed the impact of MSCs on T-cell
functions, including cytotoxicity; on dendritic cell functions
(impaired CD83 and HLA-DR expression); B-cell function and NK-
cells, deﬁned by proliferation and cytotoxicity.39 The type and
severity of adverse effects may differ based on patient populations
and the underlying disease, as well as the MSC characteristics used
for expansion and subsequent therapy. A meta-analysis of the
randomised clinical trials examining autologous and allogeneic MSC
therapy in patients, searching MEDLINE, EMBASE, and the Cochrane
Central Register of Controlled Trials (till June 2011) did not detect
associations between infusion toxicity, organ systemic complica-
tions, infections, death or malignancies. Whilst an association was
identiﬁed with MSCs and transient fever, the application of MSC was
found to be safe in 36 clinical studies. In addition, we have shown
that MSC application in patients with MDR and XDR TB is safe.40
A recent publication has addressed the increasing use of MSC in
the treatment of acute and chronic graft versus host disease (GVHD)
in transplant patients with immunomodulatory effects and have
suggested more prospective randomized controlled trials for
optimisation of the MSC therapy.31 Another recent report from
the NIH clinical centre using third-party early passage (up to passage
3) MSCs infused at 2 x 106 MSCs/kg body weight IV weekly for
3 doses in a phase I clinical trial for patients with steroid-refractory
GVHD following post-transplant complications established safety as
well as signiﬁcant rapid clinical responses and biomarker normal-
isation among the majority of the study participants. The study
observed positive outcomes in patients with a relatively intact
immune system with higher absolute lymphocyte counts and
favourable cytokine and T cell phenotype patterns.41
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Respiratory Distress syndrome and sepsis while elucidating the
challenges and bottlenecks in the ﬁeld and the clinical develop-
ment.42 The review cited the successful small randomised trial of
adipose tissue derived MSC in 12 ARDS patients in China and also of
the two ongoing allogeneic bone-marrow derived MSC trials in US as
well as an upcoming trial in Canada for patients with Septic Shock.
3. Principle of adjunct MSC treatment for TB
MSCs dampen inﬂammation through an array of interactions
with innate and adaptive immune cells thereby modulating
immune responses. MSCs, which constitute 0.001% of bone
marrow mononuclear cells (proportion declines over age), can be
easily expanded ex vivo in culture and when re-infused in patients
they home to sites of injury and inﬂammation promoting tissue
repair. The culture conditions, degree of expansion and the ﬁnal
MSCs preparations, may vary inﬂuencing clinical outcome.
Enhanced Mtb-antigen speciﬁc responses were observed
following MSC infusion in a Phase I study conducted in Belarus
patients with MDR-TB.40
An ongoing study of adjuvant autologous MSC therapy in South
African patients with MDR/XDR-TB is establishing the safety in
patients with MDR/XDR TB in Durban, King Dinuzulu Hospital
Complex and is investigating immunological mechanisms of anti-
TB responses and markers of a response to therapy. Speciﬁc efforts
have been made to study responses to MSC treatment deﬁned by
HR-CT imaging as well as to assess the best incremental value of
this adjuvant therapy in the subset of patients who would beneﬁt
from this mode of cellular therapy, compared to other possible
immune-interventions targeting the host immune response.43
4. MSC clinical trials registered at www.Clinicaltrials.gov/
On searching the www.clinicaltrials.gov web site, accessed on
November 15, 2014 using the term ‘‘mesenchymal stem cell’’,
437 studies were identiﬁed. Figure 1 depicts the clinical trials/studiesFigure 1. Clinical studies with MSC acroby geographic location with a majority of studies ongoing in
China, Europe and USA. Using the search term ‘‘mesenchymal
stromal cell’’, 60 studies were found across the globe (Figure 1)
with 32 open ongoing studies and the highest number (8) in the
category of vascular diseases with a focus on Ischemic Stroke;
6 studies on Central Nervous System Diseases ranging from Ischemic
Stroke, Amyotrophic Lateral Sclerosis, Parkinson’s Disease, Spinal
cord injury, 6 studies in Musculoskeletal diseases – mostly in
osteoarthritis; 6 studies in Digestive system diseases in Crohn’s
disease; 4 studies in Graft vs Host Disease (GvHD, 2 at Karolinska
Institutet) and 3 studies in autoimmune diseases, i.e in Multiple
Sclerosis. Note that the safety evaluation of these trials did not show
any adverse effects nor an increased risk to viral or bacterial
infections. There are no ongoing studies with MSC therapy in Africa
and the ongoing Phase Ib/IIa clinical trial of the use of autologous
bone-marrow-derived MSCs as adjunct treatment for MDR/XDR-TB
is the ﬁrst to be conducted in Durban, South Africa.
5. Perspectives
Cellular therapy is today attracting attention and provides hope
of an alternative adjunct treatment for unmet clinical needs for a
range of chronic disorders. The concept from the large-scale
pharma-driven industrial production of a drug or biopharmaceu-
tical, may shift for certain clinical indications to a more
‘‘personalized’’, precision medicine concept. This will require
coordination and harmonisation of efforts various stakeholders to
meet international GMP and GCP standards and to show the added
value of MSCs as adjunct- or salvage therapy for a range of chronic
infectious diseases, including Tuberculosis.
6. The evolution of cellular therapy and the lessons from cancer
treatment
Adoptive Cell Therapy (ACT) has been used in the ﬁeld of
metastatic cancer, and it involves isolation of antigen-speciﬁc
immune cells, their expansion and activation ex vivo followed byss different geographical locations.
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learned’ in the context of anti-cancer directed therapies may be
of beneﬁt to the use of ‘cellular’ therapies for the adjunct treatment
of TB. An overview of cellular treatments in the ﬁelds of cancer and
infectious diseases is provided in Table 1.
Cellular therapy in cancer settings started with lymphokine
activated killer (LAK) cells given intravenously in combination
with recombinant interleukin-2 (rIL-2), generated from autologous
lymphocytes harvested from patients by leukapheresis, followed
by activating the cells with rIL-2.44 Objective tumor reduction
could be achieved in patients with metastatic renal cell carcinoma,
melanoma and colorectal carcinoma. Toxicities of high-dose IL-2,
e.g. ﬂuid retention and pulmonary edema limited this therapy. This
approach was further optimised with the addition of other
biological response modiﬁers (such as interferons), and chemo-
therapeutic agents (especially cyclophosphamide, acting via
removal of regulatory T-cells, Tregs) aiming to induce long-term
memory T-cell responses directed against MHC class I- or MHC
class II-presented epitopes to target-speciﬁc T-cells.45
Tumor inﬁltrating lymphocytes (TILs) were isolated from
freshly resected melanomas and expanded ex vivo before infusing
autologous TILs back to the patient along with rIL-2 based on the
idea that TIL are enriched for antigen-experienced T-cells that
would beneﬁt from ex vivo expansion and removal of adverse
factors, such as TGFb or IL-10, elaborated in the tumor
microenvironment. ‘Conditioning’, i.e. treatment – induced lym-
phophenia, that provides ‘space’ for expansion of the adoptively
transferred antigen-speciﬁc T-cells, reduces the competition for
growth factors leads to the removal of Tregs associated with
increased objective clinical responses.46
Lymphocytes were modiﬁed by retroviral gene transduction
with a neomycin marker47 in order to track the infused immune
cells in the patients. These data provided evidence that objective
clinical responses are generated by (infused) T-cells inﬁltrating
into tumor lesions, it also provided clinically relevant information
on how retrovirus-mediated gene transfer in humans can be
administered safely and effectively.
To strengthen the T cell reactivity to nominal target antigen(s),
and to overcome T-cell tolerance, T cells are engineered through
regulated introduction of genes that encode high afﬁnity tumor-
targeting T cell receptor (TCRs) or synthetic Chimeric Antigen
Receptors (CARs). CARs use an engineered antibody fragment to
recognise the target cell and link this artiﬁcially to a number of
signalling domain proteins within the T cell designed to ‘‘switch
the T cell on’’ once the antibody recognition fragment (for example,
the CD19 B cell protein) has bound to a target cell. However,Table 1




LAK cells rIL-2 
TIL IL-2 & focus with Private Ag 
Anti-CTLA4 
Anti-CTLA4, Anti-PD-L1, Anti-4-1-BB, Anti-CD
DC Transfected by t-RNA from Resected tumor 
DC + TIL 
CMV-speciﬁc CD8 T cell clones IL-2 + repeated Ag 
CD19 CAR T Cells 
CAR-modiﬁed T cells 
Anti-viral reactive T cells 
NK Cells although not HLA-restricted, CARs are limited by the low number
of antibody targets available to re-direct the T cell.48,49 Anti-
pathogen directed CARs may also represent a viable option for the
treatment of infectious pathogens, although caution must be
exercised concerning dangerous ‘off-target toxicity’ that may cause
serious medical complications, some of them associated with the
‘cytokine storm’ induced by high antigen load.
Transformed or virally infected cells typically present processed
peptides (epitopes) from viral proteins, this is also true for tumor-
associated (mutant or non-mutant) target epitopes on their surface
in association with major-histocompatibility antigens (MHC) class
I or – class II. T cells are educated early in the development process
in thymus to prevent recognition of self-antigen(s) reﬂected in the
very low afﬁnity of binding to self-antigen(s). Several groups have
now established novel technology to enhance the natural TCR
afﬁnity to either viral or cancer protein epitopes overcoming these
obstacles to develop TCRs that could be used to target (cancer or
infectious pathogen) speciﬁc proteins displayed by MHC class I or –
class II molecules; however, the TCR would have to be transferred
into recipient effector T-cells, using either lentiviral vectors, non-
viral plasmid-based vector systems, or alternatively, RNA-based
transfer of TCRs conferring immune-reactivity, i.e. reactivity to
molecularly deﬁned targets displayed by transformed or infected
cells. Further reﬁnement in the T-cell engineering was achieved
through combinatorial antigen recognition with balanced signal-
ling by transducing T cells with both a CAR providing suboptimal
activation upon binding of one antigen and a chimeric costimu-
latory receptor (CCR) that recognises a second antigen, thereby
promoting selective target eradication.50
7. TIL & DC combination
Induction of therapeutically useful antitumor immunity in
cancer patients requires the development of powerful vaccination
protocols due to the preexisting antigenic load and immunosup-
pressive environment within a tumor. Autologous Dendritic cells
(DC) loaded ex vivo with tumor antigens by transfecting whole RNA
of the resected tumor have been tried successfully in metastatic
melanoma patients,51,52 an approach that could also be discussed
in chronic viral or bacterial infections.
TIL infusion has therefore been combined with dendritic cell
(DC) vaccination52 (for patients with stage IV melanoma) to induce
strong and long-lived T-cell memory responses. Analysis of the
T cell receptor repertoire revealed the presence of highly dominant
clones in most infusion products, and many of these could be
detected in the circulation for weeks after T cell transfer. It isClinical conditions used in Ref
Metastatic renal cell carcinoma, 44




40 Advanced cancer 63
Metastatic Melanoma 8
Stage IV Melanoma 9
Post-transplant CMV inf 10,11
ALL, CLL, NHL 17
HIV 64–66
Post-Transplant patients against CMV/ENV/HP6/Adeno 12,67
Advanced non-small cell lung cancer 68
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therapy and IL-2 will most likely increase treatment efﬁcacy with
this approach.
In an infectious disease context, initial cell therapy was tried in
life-threatening infections such as cytomegalovirus (CMV) infec-
tions in post-transplant settings with allogeneic bone marrow
transplant as a consequence of severe and prolonged immunode-
ﬁciency. CMV speciﬁc CD8+ T cell clones were generated from
peripheral blood mononuclear cells of the respective bone marrow
donors using repeated antigen stimulation along with IL-2 and
were adoptively transferred to the post-transplant patients. These
CMV-speciﬁc CD8+ T cells persisted for at least 12 weeks and were
effectively in vivo augmented by transfer of CMV speciﬁc CD4+
T cells.53,54
T cells targeting a range of viral antigens derived from EBV,
CMV, and AdV were reproducibly generated in a single culture over
a 2-3-week period, using methods that exclude all viral
components and employ a much-simpliﬁed culture technology.
When administered to recipients of post-transplant patients with
active CMV (n = 3), AdV (n = 1), EBV (n = 2), EBV+AdV (n = 2) or
CMV+AdV (n = 2) infections, the cells produced complete virologi-
cal responses in 80%, including all patients with dual infections
correlating with an increase in the frequency of T cells directed
against the infecting pathogens without immediate or delayed
toxicities.55
‘‘Off the shelf,’’ or banked, partially human leukocyte antigen
(HLA)–matched multi-virus-speciﬁc T cells (mVSTs) were gener-
ated using single T cell lines from stem cell donors upon
restimulations with overlapping peptide libraries for up to ﬁve
viruses (AdV, EBV, CMV, BKV, and HHV6) representing the most
frequent causes of viral morbidity and mortality after HSCT. This
was tried in 11 recipients of allogeneic transplants, 8 of whom had
up to four active infections with the targeted viruses and was
proven safe in all subjects and produced an overall 94% virological
and clinical response rate that was sustained long-term.56 TB
along with Epstein-Barr virus-associated lymphoproliferative
disorders and cytomegalovirus infection has been reported
in an allogeneic stem cell transplant recipient for refractory
acute myeloid leukemia, uncommon in a TB non-endemic
region.57
8. IMMUNOLOGICAL CHECKPOINT INHIBITORS: Blocking
CTLA-4 and PD-1
Many attempts are ongoing to integrate further controls in CAR
based ACT (Adoptive Cell Therapy) by regulating gene expression
and the immune cell kinetics in vivo in combination with novel
checkpoint inhibitors and cytokines. Our understanding concern-
ing the role of cell-surface inhibitory molecules has increased;
blocking these inhibitory receptors, termed ‘checkpoint modu-
lators’, such as anti-CTLA- 4 (cytotoxic T-lymphocyte-associated
protein 4; also known as CD152 which act as a major negative
regulator of T-cell responses) in patients with metastatic
melanoma leads to increased overall survival55 in a subset of
patients.
The Programmed death 1 receptor (PD-1) and its ligands (PD-
Ls) molecules inhibit T cell effector functions during active
infection. Furthermore, the simultaneous blockage of the inhibi-
tory receptor PD-1 together with the activation of the costimu-
latory protein signaling lymphocytic activation molecule resulted
in promotion of protective IFN-g responses to Mtb, even in
patients with weak cell-mediated immunity against the patho-
gen. PD-1 has been demonstrated to interfere with T cell effector
functions against Mtb, suggesting its key regulatory role during
the immune response of the host to the pathogen.58 Anti-PD-1
responses will most likely help to overcome T-cell anergy inpatients with TB, although caution has to be exercised: i) treating
patients with reagents targeting PD-1 may lead to autoimmune
responses, ii) PD-1 expression on immune cells may not only
indicate immune ‘exhaustion’, but also identify T-cells that are
antigen-experienced (and therefore interfere with pathogen-
directed T cells).
Upon infection, antigen-speciﬁc CD4 and CD8 T cells undergo
activation and perform effector functions. In chronic infections
such as TB, prolonged persistence of the Mtb leads to alteration of
function of pathogen-speciﬁc T cells, ultimately resulting in
immune exhaustion. CD4 T cells have been shown to be exhausted
and functionally unresponsive following persistent CMV infections
and this has also been seen in CD8+ T cells in metastasis from
melanoma patients. TLRs (Toll like receptors) operate synergisti-
cally to induce optimal immune responses against intracellular
pathogens. In an TB animal model, prolonged TCR stimulation of
naive CD4 T cells under Th1-polarizing conditions resulted in an
exhausted phenotype which could be limited through TLR-2 by
downregulating the expression of PD-1 and Lag-3 and increasing
the expression of IFNg, Bcl-2, and IL-2 through Tbet dependent
signalling.59 PD-1– and Lag-3–blocking therapy may therefore
hold promise in treating chronic infections.
In summary, antibodies targeting negative regulatory mole-
cules such as programmed death 1 (PD-1) and cytotoxic T-cell
lymphocyte-associated antigen 4 (CTLA-4) can be infused to
release the brakes on natural T cells response to transformed cells,
thereby augmenting the response. Chemotherapy can reduce
immune suppressive cells such as Tregs and myeloid-derived
suppressor cells (MDSC) in addition to its direct effect on the tumor
cells. Adoptive T-cell transfer strategies using clonally expanded
cytotoxic T cells or T cells engineered to express TCRs or CARs are
being tested in various cancers including haematological malig-
nancies;60 TCRs or CARS directed against M. tuberculosis may have
the potential in the adjunct treatment of tuberculosis.
9. Outlook
Tran and colleagues have merged T cell therapy with tumor
exome sequencing and provided a proof of concept that T cells
recognize tumor-speciﬁc mutations; culturing and expanding
these T cells followed by subsequent transfer of these T-cells back
to the patient has been proven to be sufﬁcient to mediate tumor
regression. Resected lung metastases from a patient with
metastatic cholangiocarcinoma were used as a source of tumor
and T cells. After identiﬁcation of 26 nonsynonymous mutations, a
CD4+ T cell population that speciﬁcally recognized a mutant
epitope from erbb2-interacting protein (ERBB2IP) was identiﬁed,
expanded, and cloned; the T cell receptor was sequenced; and its
speciﬁcity conﬁrmed.61 The patient received two infusions of
cultured and expanded tumor-inﬁltrating lymphocytes; condi-
tioning chemotherapy and cytokine support were administered to
improve engraftment of the cells. The patient experienced a
marked tumor regression after each infusion: This is a prime
example that the patient’s immune system targets mutations and
that T-cells directed against mutant epitopes are able to confer
tumor regression. A similar situation may be feasible for T-cells
recognizing wild-type and/or mutant epitopes in Mtb.
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